Pharmacoeconomics of voriconazole

Bibliography

• McNeil MM, Nash SL, Hajjeh RA, Trends in mortality due to invasive mycotic diseases in the United States, 1980 – 1997. Clin Infect Dis 2001;33:641-7
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Fungal infections. Proc Am Thorac Soc 2006;3:35-40
   PubMedGoogle Scholar
• Scott LJ, Simpson D. Voriconazole. A review of its use in the management of invasive fungal infections. Drugs 2007;67:269-98
   PubMed Web of Science ®Google Scholar
• Boucher HW, Groll AH, Chiou CC, Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020
   PubMed Web of Science ®Google Scholar
• Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005;366:1013-25
   PubMed Web of Science ®Google Scholar
• Grau S. Coste-efectividad de voriconazol. Rev Esp Quimioter Mongr 2009;2:41-7
   Google Scholar
• Wilson L, Reyes C, Stolpman M, The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26-34
   PubMed Web of Science ®Google Scholar
• Rentz AM, Halpern MT, Bowden R. The impact of candidaemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781-8
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000;31:1524-8
   PubMed Web of Science ®Google Scholar
• Epstein JB, Polsky B. Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin Ther 1998;20:40-57
   PubMed Web of Science ®Google Scholar
• Wingard JR, Herbrecht R, Mauskopf J, Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis 2007;9:128-35
   Google Scholar
• Bates DW, Su L, Yu DT, Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-18
   PubMed Web of Science ®Google Scholar
• Ullman AJ, Sanz MA, Tramarin A, Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006;43(4):e29-38
   PubMedGoogle Scholar
• Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006;55:809-18
   PubMed Web of Science ®Google Scholar
• Al-Mohsen I, Hughes WT. Systemic antifungal therapy: past, present and future. Ann Saudi Med 1998;18:28-38
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Sobel JD, Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Skiest DJ, Nieto L, A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:1179-86
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Disease Society of America. Clin Infect Dis 2009;48:503-35
   PubMed Web of Science ®Google Scholar
• Azanza JR, Urdaneta MM, García E, Voriconazol. Propiedades farmacocinéticas y farmacodinámicas, interacciones y monitorización terapéutica. Rev Esp Quimioter Mongr 2009;2:12-6
   Google Scholar
• Shehab N, DePestel DD, Mackler ER, Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy 2007;27:970-9
   PubMedGoogle Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60
   PubMed Web of Science ®Google Scholar
• Dixon S, McKeen E, Tabberer M, Economic evaluations of treatments for systemic fungal infections. A systematic review of the literature. PharmacoEconomics 2004;22:421-33
   PubMed Web of Science ®Google Scholar
• Johnson MD, Kleinberg M, Danziger L, Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions. Expert Opin Pharmacother 2005;6:2617-32
   PubMed Web of Science ®Google Scholar
• Moeremans K, Annemans L. Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients. Expert Opin Pharmacother 2006;7:1931-43
   PubMed Web of Science ®Google Scholar
• Blot SI, Vandewoude KH, Hoste EA, Effects of nosocomial candidaemia on outcomes of critically ill patients. Am J Med 2002;113:480-5
   PubMed Web of Science ®Google Scholar
• Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002;17:168-75
   PubMed Web of Science ®Google Scholar
• Olaechea PM, Palomar M, Leon-Gil C, Economic impact of Candida colonization and Candida infection in the critically patient. Eur J Clin Microbiol Infect Dis 2004;23:323-30
   PubMedGoogle Scholar
• Slavin M, Fastenau J, Sukarom I, Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis 2004;8:111-20
   PubMed Web of Science ®Google Scholar
• Laupland KB, Gregson DB, Church DL, Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005;56:532-7
   PubMed Web of Science ®Google Scholar
• Sheng WH, Wang JT, Lu DC, Comparative impact of hospital-acquired infections on medical costs, length of hospital stay and outcome between community hospitals and medical centres. J Hosp Infect 2005;59:205-14
   PubMed Web of Science ®Google Scholar
• Wey SB, Mori M, Pfaller MA, Hospital-acquired candidaemia. The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Argon J, Chu J, The epidemiology and attributable outcomes of candidaemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9
   PubMed Web of Science ®Google Scholar
• Morgan J, Meltzer MI, Plikaytis BD, Excess mortality, hospital stay, and cost due to candidaemia: a case-control study using data from population-based candidaemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-7
   PubMed Web of Science ®Google Scholar
• Gagne JJ, Breitbart RE, Maio V, Cost associated with candidaemia in a hospital setting. Pharm Ther 2006;31:586-619
   Google Scholar
• Zaoutis TE, Heydon K, Chu J, Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006;117:711-6
   PubMed Web of Science ®Google Scholar
• Craver CW, Blanchette CM, Gasper S. Costs and outcomes associated with fluconazole treatment failure for invasive Candida infection in hospitalized patients. Am J Health Sys Pharm 2006:P252E
   Google Scholar
• Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol 2008;46:97-112
   PubMed Web of Science ®Google Scholar
• Wingard JR, Kubilis P, Lee L, Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7
   PubMed Web of Science ®Google Scholar
• Cagnoni PJ, Walsh TJ, Prendergast MM, Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476-83
   PubMed Web of Science ®Google Scholar
• Hennen CR. Pharmacoeconomic evaluations of antifungal therapies. Curr Med Res Opin 2009;25:1751-8
   PubMedGoogle Scholar
• Herbrecht R, Denning DW, Patterson TF, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34
   PubMed Web of Science ®Google Scholar
• Calabró A, Follador W. Custo-efectividade de voriconazol versus anfotericina B no tratamiento da aspergilose invasiva. RBM Rev Bras Med 2003;60:528-35
   Google Scholar
• Marbaix S, Marciniak A, De Mees V, Cost-effectiveness of voriconazole compared with conventional amphotericin B in first line treatment of invasive aspergillosis in Belgium. Value Health 2003;6:750
   Google Scholar
• Soto J, Grau S, Mateu-de Antonio J. Eficiencia de voriconazol (V-FEND) en el tratamiento de la aspergilosis invasiva. Rev Esp Econ Salud 2003;2:358-62
   Google Scholar
• Rotstein C, Cragin L, Laverdière M, ; the Canadian Expert Panel. Economic evaluation of voriconazole for the treatment of candidaemia in Canadian adults. Can J Infect Dis Med Microbiol 2008;19:219-26
   PubMedGoogle Scholar
• Garbino J, Schnetzler G, Roberts C. Invasive aspergillosis: is treatment with “inexpensive” amphotericin B cost-saving if “expensive” voriconazole is only used on demand? Swiss Med Wkly 2005;135:624-30
   Google Scholar
• Grau S, Mateu-de Antonio J, Soto J, Evaluación económica del uso de voriconazol versus anfotericina B en el tratamiento de la aspergilosis invasiva. Farm Hosp 2005;29:5-10
   PubMedGoogle Scholar
• Jansen JP, Meis JF, Blijlevens NM, Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 2005;21:1535-46
   PubMed Web of Science ®Google Scholar
• Lewis JS, Boucher HW, Lubowski TJ, Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacotherapy 2005;25:839-46
   PubMed Web of Science ®Google Scholar
• Mesrobian X, Loftus J, Roberts C, Cost-effectiveness of voriconazole versus liposomal amphotericin B for invasive aspergillosis infection in the UK. Value Health 2005;8:A20
   Google Scholar
• Wenzel R, Del Favero A, Kibbler C, Economic evaluation of voriconazole compared with conventional amphotericon B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005;55:352-61
   PubMed Web of Science ®Google Scholar
• Aiello E, Dignati C, de Vedia L, Costo-efectividad de voriconazol versus anfotericina B deoxicolato en el tratamiento inicial de aspergilosis invasiva. Rev Panam Infectol 2006;8:18-25
   Google Scholar
• Jansen JP, Kern WV, Cornely OA, Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006;9:12-23
   PubMed Web of Science ®Google Scholar
• Ravasio R, Pizzarelli G. Valutazione economica di voriconazolo versus amfotericina B convenzionale nel trattamento di prima linea dell´aspergillosi nei pazienti immunocompromessi. PharmacoEconomics Ital Res Art 2006;8:45-54
   Google Scholar
• Ament JHA, Hübben MWA, Verweij PE, Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother 2007;60:385-93
   PubMed Web of Science ®Google Scholar
• Domínguez-Gil A, Martín I, García M, Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Clin Drug Invest 2007;27:197-205
   PubMed Web of Science ®Google Scholar
• Greene RE, Mauskopf J, Roberts CG, Comparative cost-effectiveness of voriconazole and amphotericin B in the treatment of invasive pulmonary aspergillosis. Am J Health Syst Pharm 2007;64:2561-8
   PubMed Web of Science ®Google Scholar
• Van Campenhout H, Marbaix S, Derde MP, Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results. Clin Drug Investig 2008;28:509-21
   PubMed Web of Science ®Google Scholar
• Selleslag D, Vogelaers D, Marbaix S. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium. Acta Clin Belg 2009;64:393-8
   PubMed Web of Science ®Google Scholar
• Arnold T, Donegan S, Kleinberg M, Cost-effectiveness of implementing an IV antifungal to oral voriconazole conversion in a cancer center. 42nd Annual Meeting of IDSA; Boston: 178 – September 30 – October 3, 2004
   Google Scholar
• Collins CD, Stuntebeck ER, DePestel DD, Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin Drug Invest 2007;27(4):233-41
   PubMedGoogle Scholar
• Riedel A, Choe L, Inciardi J, Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect Dis 2007;7:70-6
   PubMed Web of Science ®Google Scholar
• Shehab N, DePestel DD, Mackler ER, Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy 2007;27:970-9
   PubMedGoogle Scholar
• Romá-Sánchez E, Poveda-Andrés JL, García-Pellicer J, Estudio coste-efectividad de la estrategia empírica antifúngica en pacientes oncohematológicos. Farm Hosp 2008;32:7-17
   PubMedGoogle Scholar
• Slobbe L, Polinder S, Doorduijn JK, Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008;47:1507-12
   PubMed Web of Science ®Google Scholar
• Al-Badriyeh D, Liew D, Stewart K, Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J Antimicrob Chem 2009;63:197-208
   PubMed Web of Science ®Google Scholar
• Rotstein C, Cragin L, Laverdiére M, Economic evaluation of voriconazole for the treatment of candidaemia in Canadian adults. Can J Infect Dis Med Microbiol 2008;19:219-26
   PubMedGoogle Scholar
• Sacristán JA, Oliva J, Del Llano J, What is an efficient technology in Spain? Gac Sanit 2002;16:334-43
   PubMedGoogle Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics 2008;26:733-44
   PubMed Web of Science ®Google Scholar
• Greene RE, Schlamm HT, Oestmann JW, Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-79
   PubMed Web of Science ®Google Scholar
• Cleemput I, Neyt M, Thiry N, Threshold values for cost-effectiveness in health care. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE); 2008. KCE reports 100C (D/2008/10.273/96)
   Google Scholar
• International Society for Pharmacoeconomics and Outcomes Research. ISPOR Good Outcomes Research Practices & Issues Index. Available from: http://www.ispor.org/workpaper/practices_index.asp [Last accessed January 2010]
   Google Scholar